We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Res.Phm.Reg S | LSE:RPSE | London | Ordinary Share | COM SHS USD0.0001(REG S) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMRPSE
RNS Number : 3659O
Research Pharmaceutical SRV, Inc
05 March 2009
5 March 2009
ReSearch Pharmaceutical Services Inc.
Exercise of Options
ReSearch Pharmaceutical Services, Inc. (the "Company"), a leading provider of
clinical development outsourcing solutions to the biopharmaceutical industry,
announces today the issue of 544 new shares of common stock of $0.0001 each
("Shares") relating to the exercise of outstanding employee share options at an
average exercise price of $0.37 per Share.
Application has been made for the admission to trading on AIM of 544 new Shares
and dealings in the new Shares are expected to commence on March 10, 2009. The
new Shares rank pari passu with the Company's existing issued Shares.
Following this issue, the Company will have outstanding 36,746,835 Shares and
1,357,179 Warrants (as defined in the Company's Readmission Document dated June
5, 2007) (1).
(1) These figures exclude the remaining 186,667 Unit Purchase Options and
approximately
2.9 million employee stock options which also remain
outstanding.
For further information please contact:
+--------------------------------------------------+-----------------------+
| ReSearch Pharmaceutical Services, Inc.: | +1-215-540-0700 |
+--------------------------------------------------+-----------------------+
| Daniel M. Perlman, Chairman & Chief Executive | |
| Officer | |
+--------------------------------------------------+-----------------------+
| Steven Bell, Chief Financial Officer | |
+--------------------------------------------------+-----------------------+
| | |
+--------------------------------------------------+-----------------------+
| Nominated Adviser and UK Broker: | +44-20-7012-2000 |
+--------------------------------------------------+-----------------------+
| Arbuthnot Securities Limited | |
+--------------------------------------------------+-----------------------+
| James Steel/Ed Burbidge | |
+--------------------------------------------------+-----------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISSSUSUISUSEDD
1 Year Res.Phm.Reg S Chart |
1 Month Res.Phm.Reg S Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
